Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Dna X (SONM) EBIT (2018 - 2025)

Dna X's EBIT history spans 8 years, with the latest figure at $4.7 million for Q4 2025.

  • Quarterly results put EBIT at $4.7 million for Q4 2025, down 44.74% from a year ago — trailing twelve months through Dec 2025 was -$5.4 million (down 74.39% YoY), and the annual figure for FY2025 was -$5.4 million, down 74.39%.
  • EBIT for Q4 2025 was $4.7 million at Dna X, up from -$4.0 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $8.4 million in Q4 2024 to a low of -$11.7 million in Q4 2021.
  • The 5-year median for EBIT is -$2.5 million (2024), against an average of -$3.0 million.
  • Peak annual rise in EBIT hit 772.11% in 2024, while the deepest fall reached 966.13% in 2024.
  • Year by year, EBIT stood at -$11.7 million in 2021, then surged by 90.98% to -$1.1 million in 2022, then decreased by 18.51% to -$1.3 million in 2023, then soared by 772.11% to $8.4 million in 2024, then tumbled by 44.74% to $4.7 million in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at $4.7 million, -$4.0 million, and -$6.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.